

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/615,262
Confirmation Number	5695
Filing Date	July 9, 2003
First Named Inventor	Ryuichi MORISHITA
Art Unit	Not yet assigned 1633
Examiner Name	Not yet assigned Robert M. Kelly
Attorney Docket Number	Q75926

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>o</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>o</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>o</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
RMK		NICHOLAS MILLER, et al. "Targeted vectors for gene therapy" <i>The FASEB Journal</i> , vol. 9, February 1995	

Examiner Signature

Robert M. Kelly

Date Considered

9/6/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A &amp; B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/615,262  
 Confirmation Number Not yet assigned  
 Filing Date July 9, 2003  
 First Named Inventor Ryuichi MORISHITA  
 Art Unit ~~Not yet assigned~~ 1633  
 Examiner Name ~~Not yet assigned~~ Robert M. Kelly  
 Attorney Docket Number Q75926

Sheet 1 of 1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
RHK		K. KATO, et al., "Expression of Hepatitis B Virus Surface Antigen in Adult Rat Liver. Co-introduction of DNA and Nuclear Protein by a Simplified Liposome Method", <i>J. Biol. Chem.</i> , February 25, 1991, vol. 266, no. 6, pp. 3361-4.	Abstract
RHK		F. BUSSOLINO, et al., "Hepatocyte Growth Factor is a Potent Angiogenic Factor which Stimulates Endothelial Cell Motility and Growth", <i>J. Cell Biol.</i> (1992), vol. 3, pp. 629-41.	Abstract

Examiner Signature

Robert M. Kelly

Date Considered

9/6/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	Divisional Application of Appln. No. 09/660,522
				Confirmation Number	Not yet assigned
				Filing Date	July 9, 2003
				First Named Inventor	Ryuichi MORISHITA
				Art Unit	1636 (prior application) 1633
Examiner Name	David A. Lambertson (prior application) Robert M. Kelly				
Attorney Docket Number	Q75926				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
PK	✓	EP	0 461 560	A1	12/18/91	Toshikazu Nakamura	NA
PK	✓	WO	96/40062		12/19/96	Georgetown University	NA

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>

Examiner Signature	Robert M. Kelly	Date Considered	9/6/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<i>Complete if Known</i>		
			Application Number	Divisional Application of Appln No. 09/660,522	
			Confirmation Number	Not yet assigned	
			Filing Date	June 9, 2003	
			First Named Inventor	Ryuichi MORISHITA	
			Art Unit	1636 (prior application) / 633	
			Examiner Name	D. Lambertson (prior application) Robert M. Kelly	
Sheet	1	Of	1	Attorney Docket Number	Q75926

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		December 30, 2002 Office Action issued in corresponding Taiwanese patent application.	No
TRK		ML LIU, et al., "Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine," Carcinogenesis, April 1995, 16(4): 841-3.	Abstract
		Y. MATSUDA, et al., "Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats," J. Biochem., September 1995, 118(3): 643-9.	Abstract
		G. SHIOTA, et al., "Inhibitory effect of hepatocyte growth factor on metastasis of hepatocellular carcinoma in transgenic mice," Res Commun Mol Pathol Pharmacol, January 1996, 91(1): 33-9.	Abstract
		G. SHIOTA, et al., "Characterization of double transgenic mice expressing hepatocyte growth factor and transforming growth factor alpha," Res Commun Mol Pathol Pharmacol, October 1995, 90(1): 17-24.	Abstract
		G. SHIOTA, et al., "Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression," Hepatology, April 1994, 19(4): 962-72.	
TRK		G. SHIOTA, et al., "Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells," Proc Natl Acad Sci USA, January 1992, 89(1): 373-7.	Yes

Examiner Signature	<i>Robert M. Kelly</i>	Date Considered	9/6/05
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

Form PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent & Trademark OfficeINFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

Attorney Docket: Q75926

Divisional application of Appln. No. 09/660,552

Applicant: Ryuichi MORISHITA, et al.

Filing Date: July 9, 2003

Group: 1636 (prior application) 1633

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
<i>RUK</i>	USPN 5,652,225	7/29/97	Isner et al.	514	440	
<i>RUK</i>	USPN 5,756,122	5/26/98	Thierry et al.	424	450	

## FOREIGN PATENT DOCUMENTS

Document	Date	Country	Class	Sub-class	Translation Yes/No
<i>RUK</i> ✓ WO 96 40062A	12/19/96	WIPO			
WO 91 06309A	5/16/91	WIPO			
EP 0461 560A	12/18/91	EPO			
EP 0494369	7/15/92	EPO			
EP 0492614	7/1/92	EPO			
WO 93/08821	5/13/93	WIPO			
WO 94/06456	3/31/94	WIPO			
<i>RUK</i> ✓ WO 92/05184	4/2/92	WIPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RUK</i>	Nakamura et al., "MOLECULAR CLONING AND EXPRESSION OF HUMAN HEPATOCYTE GROWTH FACTOR", Nature, Vol. 342, November 23, 1989, pages 440-443, XP000652120
	Miyazawa K. et al., "MOLECULAR CLONING AND SEQUENCE ANALYSIS OF cDNA FOR HUMAN HEPATOCYTE GROWTH FACTOR" Biochemical and Biophysical Research Communications, Vol. 163, No. 2, September 15, 1989, pages 967-973, XP000651424
	T. Seki et al., "ISOLATION AND EXPRESSION OF cDNA FOR DIFFERENT FORMS OF HEPATOCYTE GROWTH FACTOR FROM HUMAN LEUKOCYTE" Biochemical and Biophysical Research Communications Vol 172, No. 1, October 15, 1990, pages 321-327, XP002084490
	<del>Japan Financial News Paper (December 14, 1998 w/ English language translation)</del>
	<del>Local News Section of Japan Financial News Paper (December 14, 1998 w/ English language translation)</del>
	<del>Asahi News Paper (November 2, 1999 w/ English language translation)</del>
	<del>Supplement to Circulation Vol. 96, Abstract No. 3459 (October 21, 1997)</del>
	Licki et al., Nature Medicine 5:226230, 1999
	Research report from the Welfare Ministry Specific Diseases, Pervaded Lung Diseases Sub-group (1997 w/ English language translation)
	Ueda, et al., Ann. Thorac. Surg. 67:1726-1731, 1999
<i>RUK</i>	Preprint - article by Taniyama et al., entitled "Therapeutic Angiogenesis Induced by Human Hepatocyte

INFORMATION DISCLOSURE STATEMENT

Continuation of U.S. Appln. No.

last page	(continued from the last page) Growth Factor Gene in Rat and Rabbit Hind Limb Ischemia Models: Pre-clinical Study to Treat Peripheral Arterial Disease."
PKK	Preprint of article by Aoki, et al., entitled "Angiogenesis Induced by Hepatocyte Growth Factor in Non-infarcted Myocardium and Infarcted Myocardium: Up-regulation of Essential Transcription Factor for Angiogenesis, Ets."
	"Scatter Factor (Hepatocyte Growth Factor) is a Potent Angiogenesis Factor IN Vitro" by Rosen et al., Society of Experimental Biology, 1993, pp 227-234
	"Scatter Factor Induces Blood Vessel Formation IN VIVO" by Grant, et al., Proc. Nat'l. Acad. Sci USA, Vol. 90, March 1993, pp 1937-1941
	"Hepatocyte Growth Factor/Scatter Factor Modulates Cell Motility, Proliferation, and Proteoglycan Synthesis of Chondrocytes" by Takebayashi et al., Journal of Cell Biology, Vol. 29, No. 5 1995, pp 1411-1419
	"The Interaction of HGF-SF with other Cytokines in Tumor Invasion and Angiogenesis" by Rosen et al., Vol. 65, 1993, pp. 301-310
	<del>Circulation 96, No. 8, October 21, 1997, No. 3459</del>
	<del>Nature Medicine 5:226-230 (February, 1999)</del>
	<del>Nature 338:557-562, 1989</del>
	<del>Science 235:442-447, 1987</del>
	<del>J. Clin. Invest. 93:662-670, 1993</del>
	<del>J. Vasc. Surg. 16:181-191, 1998</del>
	<del>Circulation 97:645-650, 1998</del>
	<del>Circulation 98:2800-2804, 1998</del>
	<del>J. Bone &amp; Joint Surg. 71:74-80, 1989</del>
	<del>New England J. Medicine 331:889-895, 1994</del>
	<del>Gut, Supplement No. 5, Vol. 35, s-60, F240 (1994)</del>
	Biochem and Biophys Res. Comm. 220, 539-545 (1996), Hayashi et al., "Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells
	Verma et al., "Gene therapy promises, problems and prospects," Nature 389:239-242 (1997)
PKK	Morishita, et al., "Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells," Hypertension 21:894-899 (1993)
EXAMINER:	DATE CONSIDERED: 9/6/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.	

Attorney Docket: Q75926  
Divisional application of Appln. No. 09/660,552  
Applicant: Ryuichi MORISHITA, et al.  
Filing Date: July 9, 2003  
Group: 1636 (prior application) 1633

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation not in conformance and not considered. Include copy of this form with next communication.